Tocotrienols in Parkinson's Disease Trial (NCT04491383)

Overview

This Phase 2 clinical trial investigates the neuroprotective potential of tocotrienols, a potent isoform of vitamin E, in patients with [Parkinson's disease](/diseases/parkinsons-disease). The study is conducted by the National Neuroscience Institute in Singapore and represents a promising approach to disease modification through a well-tolerated nutritional intervention.

Tocotrienols have garnered significant attention in neurodegenerative disease research due to their superior neuroprotective properties compared to the more commonly used tocopherols. The trial addresses a critical unmet need in Parkinson's disease care: disease-modifying therapies that can slow or halt disease progression rather than merely managing symptoms.

Trial Details

Overview

This Phase 2 clinical trial investigates the neuroprotective potential of tocotrienols, a potent isoform of vitamin E, in patients with [Parkinson's disease](/diseases/parkinsons-disease). The study is conducted by the National Neuroscience Institute in Singapore and represents a promising approach to disease modification through a well-tolerated nutritional intervention.

Tocotrienols have garnered significant attention in neurodegenerative disease research due to their superior neuroprotective properties compared to the more commonly used tocopherols. The trial addresses a critical unmet need in Parkinson's disease care: disease-modifying therapies that can slow or halt disease progression rather than merely managing symptoms.

Trial Details

| Field | Value |
|-------|-------|
| NCT ID | NCT04491383 |
| Status | Recruiting |
| Phase | Phase 2 |
| Study Type | Interventional |
| Allocation | Randomized |
| Intervention Model | Parallel Assignment |
| Masking | Double-Blind |
| Sponsor | National Neuroscience Institute, Singapore |
| Intervention | Tocotrienols (vitamin E isoform) |
| Enrollment | 60 participants |
| Start Date | June 2020 |
| Expected Completion | December 2025 |
| Location | Singapore |

Scientific Rationale

Oxidative Stress in Parkinson's Disease

[Oxidative stress](/mechanisms/oxidative-stress) is a central mechanism in Parkinson's disease pathogenesis. The substantia nigra pars compacta (SNc) of PD patients shows evidence of:

• Elevated ROS: Increased production of reactive oxygen species
• Lipid peroxidation: Enhanced membrane damage from oxidized lipids
• DNA oxidation: Oxidative DNA damage (8-OHdG accumulation)
• Protein oxidation: Carbonyl group formation on proteins
• Mitochondrial dysfunction: Complex I deficiency increases ROS

• High metabolic demand and oxygen consumption
• Dopamine metabolism generating ROS
• Neuromelanin accumulation
• Limited antioxidant capacity

Tocotrienol Advantages Over Tocopherols

Vitamin E exists in eight isoforms divided into two classes:

| Property | Tocopherols | Tocotrienols |
|----------|-------------|--------------|
| Saturated side chain | Yes | Unsaturated (3 double bonds) |
| Tissue distribution | Limited | Broad, including CNS |
| Antioxidant potency | Moderate | 10-50× more potent |
| Cholesterol-lowering | No | Yes |
| Neuroprotection | Limited | Enhanced |

The unsaturated side chain of tocotrienols provides several advantages[@gopalan2019]:

Mechanism of Action

Tocotrienols exert neuroprotective effects through multiple pathways[@khatri2011]:

Antioxidant Effects

• ROS scavenging: Direct neutralization of free radicals
• Lipid peroxidation inhibition: Prevents membrane damage
• Endogenous antioxidant enhancement: Upregulates SOD, catalase, glutathione peroxidase
• Metal chelation: Reduces iron-catalyzed oxidative damage

Anti-Inflammatory Effects

• NF-κB inhibition: Blocks pro-inflammatory transcription factor
• COX-2 downregulation: Reduces prostaglandin synthesis
• TNF-α modulation: Decreases pro-inflammatory cytokine production
• Microglial activation: Inhibits microglial-mediated neuroinflammation

Mitochondrial Protection

• Complex I preservation: Protects mitochondrial electron transport
• ATP maintenance: Preserves cellular energy production
• Apoptosis inhibition: Prevents mitochondrial pathway of cell death
• Mitophagy enhancement: Promotes clearance of damaged mitochondria

Neuroprotective Signaling

• AMPK activation: Enhances cellular stress resilience
• mTOR modulation: Promotes autophagy
• SIRT1 activation: Supports cellular longevity pathways
• FOXO3a deacetylation: Enhances antioxidant gene expression

Additional Mechanisms

• NMDA receptor modulation: Reduces excitotoxicity
• Calcium homeostasis: Stabilizes intracellular calcium
• Autophagy induction: Enhances protein aggregate clearance
• Synaptic protection: Preserves synaptic function

Study Design

Treatment Arms

| Arm | Intervention | Dose | Duration |
|-----|-------------|------|----------|
| Active | Tocotrienols (mixed isoforms) | TBD | 12 months |
| Placebo | Matching placebo | N/A | 12 months |

Inclusion Criteria

Exclusion Criteria

Outcome Measures

Primary Endpoints

Motor Function

• Unified Parkinson's Disease Rating Scale (UPDRS) Part III
• Change from baseline to 12 months
• Assessed in OFF and ON medication states
• Administered by certified raters

Safety Assessment

• Adverse event monitoring
• Vital signs
• Laboratory values (lipid panel, liver function)
• Bleeding risk assessment

Secondary Endpoints

Quality of Life

• PDQ-39: Parkinson's Disease Questionnaire-39
• MDS-UPDRS Parts I, II, IV: Non-motor experiences, daily activities, motor complications

Cognitive Function

• MoCA: Montreal Cognitive Assessment
• Trail Making Test: Executive function assessment

Biomarker Analysis

• Oxidative stress markers:
• 8-OHdG (DNA oxidation)
• Malondialdehyde (lipid peroxidation)
• Total antioxidant capacity
• Inflammatory markers:
• IL-6, TNF-α
• Neurodegeneration markers:
• Neurofilament light chain (NfL)

Neuroimaging (in subset)

• DaT SPECT imaging
• MRI volumetric analysis

Preclinical Evidence

Animal Model Studies

Tocotrienols have demonstrated neuroprotection in multiple PD models[@peng2012]:

| Model | Findings |
|-------|----------|
| MPTP model | Preserved TH+ neurons, improved behavior |
| 6-OHDA model | Reduced lesion volume, enhanced DA release |
| Alpha-synuclein transgenic | Reduced aggregation, improved survival |
| Rotenone model | Restored mitochondrial function |

Mechanism Studies

• Reduced lipid peroxidation in substantia nigra
• Preserved complex I activity
• Decreased microglial activation
• Enhanced autophagy flux
• Reduced alpha-synuclein aggregation

Clinical Evidence Context

Vitamin E and PD Risk

Epidemiological studies have examined vitamin E and Parkinson's disease risk[@molinuevo2020]:

| Study | Finding |
|-------|---------|
| Health Professionals Follow-up | High vitamin E intake associated with reduced PD risk |
| Nurses' Health Study | Moderate association |
| Finnish Mobile Clinic | No significant association |
| Meta-analysis | Possible protective effect for dietary vitamin E |

Note: These studies largely examined tocopherols; tocotrienols have not been studied as extensively in humans.

Safety Profile

Tocotrienols have a favorable safety profile at typical doses:

| Adverse Event | Frequency | Notes |
|--------------|-----------|-------|
| Gastrointestinal upset | Rare | Usually mild |
| Bleeding risk | Theoretical | Monitor in anticoagulated patients |
| Headache | Rare | Usually transient |

Maximum tolerated dose in humans: ~1000mg/day

Expected Outcomes and Clinical Significance

Primary Expected Outcomes

Clinical Implications

If successful, this trial would establish:

• Disease-modifying option: First disease-modifying nutritional intervention
• Accessible therapy: Low-cost, widely available treatment
• Combination potential: Synergy with dopaminergic medications
• Prevention approach: Potential for use in prodromal PD

Comparison to Other Neuroprotective Trials

| Trial | Intervention | Target | Status |
|-------|-------------|--------|--------|
| NCT04491383 | Tocotrienols | Antioxidant | Recruiting |
| NCT06162013 | NAD+ precursors | Metabolic | Recruiting |
| INMOND | Inosine | Urate | Completed |
| TIRAMISU | Talidomide analogs | Neuroinflammation | Terminated |

Cross-References

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Oxidative Stress in PD](/mechanisms/oxidative-stress-pd)
• [Neuroinflammation Mechanism](/mechanisms/neuroinflammation)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Vitamin E and Neuroprotection](/therapeutics/vitamin-e-pd)
• [Tocotrienols as Dietary Supplements](/nutrients/tocotrienols)
• [Alpha-Synuclein Aggregation](/proteins/alpha-synuclein)

External Links

• [ClinicalTrials.gov - NCT04491383](https://clinicaltrials.gov/study/NCT04491383)
• [National Neuroscience Institute Singapore](https://www.nni.com.sg/)
• [Michael J. Fox Foundation - PD Research](https://www.michaeljfox.org/)
• [Parkinson's Foundation](https://www.parkinson.org/)

References

See Also

• [SIRT1 Gene](/wiki/genes-sirt1) — references
• [TH Gene](/wiki/genes-th) — references